The Centers for Medicare and Medicaid Services (CMS), in a final national policy decision, is allowing Medicare to cover the cost of Aduhelm (aducanumab) and other medicines in its class given accelerated approval only for Alzheimer’s disease patients enrolled in qualifying clinical trials. Should Adulhelm or future amyloid-targeting monoclonal antibodies be given standard or full — rather than accelerated — FDA approval, CMS will broaden Medicare’s coverage to include people on those treatments enrolled in real-life studies “with…
April 12, 2022April 12, 2022